Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Por um escritor misterioso
Descrição
NASH Target Development Service for DAG O-Acyltransferase (DGAT
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the
PDF] MGAT2, a Monoacylglycerol Acyltransferase Expressed in the
Inhibition of MGAT2 modulates fat‐induced gut peptide release and
MGAT2 inhibitor decreases liver fibrosis and inflammation in
Emerging novel targets for nonalcoholic fatty liver disease
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the
DualAG decreased TG synthesis in DIO mice. A. Monoacylglycerol
Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated
A Class of Diacylglycerol Acyltransferase 1 Inhibitors Identified
BMS-963272Cas# 1441057-15-3
US9701672B2 - Dihydropyridinone MGAT2 inhibitors for use in the
Targeted therapeutics and novel signaling pathways in non-alcohol
de
por adulto (o preço varia de acordo com o tamanho do grupo)
